Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
WALTHAM, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 8th Annual Biotech Showcase™ Conference on Monday, January 11, 2016 at 11:30 AM PST at the Parc 55 Hotel in San Francisco, CA.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
The Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
